Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of SB-497115 for chemotherapy-induced thrombocytopenia in advanced solid tumors
2004-000368-28Phase 2Completed
- Sponsor
- GSK
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of eltrombopag in chemotherapy-induced thrombocytopenia (CIT) (4 arms), sponsored by GSK. Primary endpoint: Change in platelet count from day 1 in cycle 2 to cycle 2 nadir. Started May 2005; status: completed.
02
Drugs
eltrombopag
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on 2004-000368-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000368-28.